ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.36
0.17%
US Tech 100
20,795.20
-0.88%
S&P 500
6,037.88
0.72%
US Dollar vs CAD
1.42752
-0.41%
Bitcoin
97,854.79
-0.01%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Kymera Therapeutics Inc (KYMR)

  7. Kymera Therapeutics Inc (KYMR) News

KYMR

Kymera Therapeutics (KYMR)

Kymera Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KYMR
DateTimeSourceHeadlineSymbolCompany
01/30/20256:00AMGlobeNewswire Inc.Kymera Therapeutics to Participate in Upcoming February Investor ConferencesNASDAQ:KYMRKymera Therapeutics Inc
01/14/20253:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KYMRKymera Therapeutics Inc
01/14/20256:00AMGlobeNewswire Inc.Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology ProgramsNASDAQ:KYMRKymera Therapeutics Inc
01/13/20256:00AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYMRKymera Therapeutics Inc
01/13/20256:00AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYMRKymera Therapeutics Inc
01/07/20256:00AMGlobeNewswire Inc.Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14NASDAQ:KYMRKymera Therapeutics Inc
11/26/20246:00AMGlobeNewswire Inc.Kymera Therapeutics to Participate in Upcoming December Investor ConferencesNASDAQ:KYMRKymera Therapeutics Inc
11/05/20246:00AMGlobeNewswire Inc.Kymera Therapeutics to Participate in Upcoming November Investor ConferencesNASDAQ:KYMRKymera Therapeutics Inc
10/31/20247:13AMEdgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:KYMRKymera Therapeutics Inc
10/31/20246:45AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KYMRKymera Therapeutics Inc
10/31/20246:40AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KYMRKymera Therapeutics Inc
10/31/20246:30AMGlobeNewswire Inc.Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:KYMRKymera Therapeutics Inc
10/24/20246:00AMGlobeNewswire Inc.Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory DiseasesNASDAQ:KYMRKymera Therapeutics Inc
10/23/20246:15AMGlobeNewswire Inc.Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31NASDAQ:KYMRKymera Therapeutics Inc
10/23/20246:00AMGlobeNewswire Inc.Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 SymposiumNASDAQ:KYMRKymera Therapeutics Inc
10/09/20246:00AMGlobeNewswire Inc.Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 DegraderNASDAQ:KYMRKymera Therapeutics Inc
09/25/20246:00AMGlobeNewswire Inc.Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV CongressNASDAQ:KYMRKymera Therapeutics Inc
08/28/20246:00AMGlobeNewswire Inc.Kymera Therapeutics to Participate in Upcoming September Investor ConferencesNASDAQ:KYMRKymera Therapeutics Inc
08/21/202410:15AMGlobeNewswire Inc.Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:KYMRKymera Therapeutics Inc
08/20/20244:24PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KYMRKymera Therapeutics Inc
08/20/20243:31PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KYMRKymera Therapeutics Inc
08/19/20249:45PMGlobeNewswire Inc.Kymera Therapeutics Announces Pricing of $225 Million Public OfferingNASDAQ:KYMRKymera Therapeutics Inc
08/19/20243:01PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KYMRKymera Therapeutics Inc
08/19/20243:01PMGlobeNewswire Inc.Kymera Therapeutics Announces Proposed Public OfferingNASDAQ:KYMRKymera Therapeutics Inc
08/07/20246:15AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KYMRKymera Therapeutics Inc
08/07/20246:10AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KYMRKymera Therapeutics Inc
08/07/20246:00AMGlobeNewswire Inc.Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:KYMRKymera Therapeutics Inc
07/31/20246:00AMGlobeNewswire Inc.Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7NASDAQ:KYMRKymera Therapeutics Inc
07/16/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KYMRKymera Therapeutics Inc
07/16/20243:28PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KYMRKymera Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KYMR

Your Recent History

USOTC
RDGL
Vivos (QB)
USOTC
CLHI
CLST (PK)
USOTC
PHIL
PHI (PK)
USOTC
AXXA
Exxe (PK)
USOTC
AABB
Asia Broadband (PK)
USOTC
ASII
Accredited Solutions (PK)
USOTC
TGLO
TheGlobe com (PK)
NASDAQ
LWLG
Lightwave Logic
USOTC
RSPI
RespireRx Pharmaceuticals (CE)
USOTC
INKW
Greene Concepts (PK)
USOTC
FNMA
Fannie Mae (QB)
USOTC
MGON
Megola (PK)
NYSE
IONQ
IonQ
USOTC
BMXI
Brookmount Explorations (PK)
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
NASDAQ
COOP
Mr Cooper
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads